Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals has reported Other Accumulated Expenses for 9 years, with the latest figure at $1.8 million in Q2 2025.

• For the quarter ending Q2 2025, Other Accumulated Expenses rose 66.42% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2025 stood at $1.8 million (up 66.42% YoY), and the FY2024 full-year result was $901000.0, down 72.42% from the prior year.
• Other Accumulated Expenses for Q2 2025 stood at $1.8 million, up from $1.7 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.3 million in Q4 2023, with the low at $335000.0 in Q4 2022.
• Average Other Accumulated Expenses over 5 years is $1.1 million, with a median of $925500.0 recorded in 2021.
• Year-over-year, Other Accumulated Expenses jumped 875.22% in 2023 and sank 72.42% in 2024.
• Tracing CRNX's Other Accumulated Expenses over 5 years: stood at $939000.0 in 2021, then tumbled by 64.32% to $335000.0 in 2022, then jumped by 875.22% to $3.3 million in 2023, then slumped by 72.42% to $901000.0 in 2024, then surged by 99.67% to $1.8 million in 2025.
• The last three Other Accumulated Expenses figures came in at $1.8 million (Q2 2025), $1.7 million (Q1 2025), and $901000.0 (Q4 2024), per Business Quant data.

Peer Comparison